Filters:
Organization: NeuroScios GmbH1 Projects | 1 Researchers | $3,809,420 Invested
2024
NeuroScios GmbH
Giacomo Koch, MD, PhD
Phase 3 trial of dopaminergic therapy in patients with Alzheimer’s disease.
Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.
Giacomo Koch, MD, PhD
Phase 3 trial of dopaminergic therapy in patients with Alzheimer’s disease.